Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -69 | -356 | -199 | -122 | 17 |
| Depreciation Amortization | 25 | 105 | 79 | 54 | 27 |
| Accounts receivable | 336 | 539 | 638 | 526 | 330 |
| Accounts payable and accrued liabilities | -433 | -120 | -769 | -636 | -209 |
| Other Working Capital | -28 | 833 | 93 | -213 | -78 |
| Other Operating Activity | 53 | -450 | 233 | 157 | -125 |
| Operating Cash Flow | $-117 | $552 | $75 | $-234 | $-38 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | -54 | -37 | -34 | -32 |
| Purchase Of Investment | -14 | -512 | -398 | -405 | -172 |
| Other Investing Activity | 9 | 115 | 35 | 19 | 7 |
| Investing Cash Flow | $-5 | $-451 | $-401 | $-419 | $-197 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | -34 | -34 | -34 | N/A |
| Common Stock Issued | N/A | 150 | 150 | 150 | N/A |
| Other Financing Activity | -2 | -8 | -6 | -4 | 0 |
| Financing Cash Flow | $-2 | $108 | $110 | $112 | $N/A |
| Exchange Rate Effect | -22 | -215 | -447 | -243 | -45 |
| Beginning Cash Position | 2,119 | 2,124 | 2,124 | 2,124 | 2,124 |
| End Cash Position | 1,973 | 2,119 | 1,462 | 1,340 | 1,844 |
| Net Cash Flow | $-146 | $-5 | $-662 | $-784 | $-280 |
| Free Cash Flow | |||||
| Operating Cash Flow | -117 | 552 | 75 | -234 | -38 |
| Capital Expenditure | 0 | -54 | -37 | -34 | -32 |
| Free Cash Flow | -117 | 498 | 38 | -267 | -70 |